DeepMed Research

The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Intra-operative Assessment of Cavernosal Nerve Stimulus Threshold

Not Applicable

Completed

Conditions: Prostatectomy

Interventions: Device: 10Hz + 100 micro-seconds
Device: 10Hz + 200 micro-seconds
Device: 7Hz + 100 micro-seconds
Device: 7Hz + 200 micro-seconds

First Posted Date: 2017-05-12

Last Posted Date: 2020-02-12

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 6

Registration Number: NCT03150758

Locations: 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

PSA TOOL for Prostate Cancer Screening Discussions

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Behavioral: Revised PSA TOOL
Behavioral: PSA TOOL
Behavioral: Informal Interview

First Posted Date: 2017-05-01

Last Posted Date: 2018-05-11

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 95

Registration Number: NCT03135444

Locations: 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Sensation After Nipple Sparing Mastectomy and Breast Reconstruction With or Without Neurotized Free Tissue Transfer

Not Applicable

Withdrawn

Conditions: Mastectomy
Breast Reconstruction

Interventions: Procedure: Autologous Breast Reconstruction
Procedure: Breast Reconstruction with Artificial Implant
Procedure: Neurotization

First Posted Date: 2017-05-01

Last Posted Date: 2018-11-14

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT03135392

Locations: 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Can Making Video Narratives Benefit Adolescents With Cancer

Not Applicable

Withdrawn

Conditions: Pediatric Cancer

Interventions: Behavioral: Video narrative
Behavioral: PedsQL
Behavioral: Ten Item Personality Inventory
Behavioral: Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test
Behavioral: The Cognitive Log

First Posted Date: 2017-04-25

Last Posted Date: 2020-04-09

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT03127254

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

Phase 2

Completed

Conditions: Metastatic Renal Cell Carcinoma

Interventions: Drug: Nivolumab
Drug: Ipilimumab

First Posted Date: 2017-04-24

Last Posted Date: 2024-03-18

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 26

Registration Number: NCT03126331

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Optimization of Ureterolysis During Hysterectomy

Not Applicable

Withdrawn

Conditions: Hysterectomy

Interventions: Device: Ureteral Illuminating Catheter

First Posted Date: 2017-04-21

Last Posted Date: 2018-02-27

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT03123315

Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer

Phase 2

Completed

Conditions: Metastatic Triple Negative Breast Cancer

Interventions: Drug: Carboplatin
Drug: Nab-paclitaxel
Drug: Pembrolizumab

First Posted Date: 2017-04-20

Last Posted Date: 2023-10-06

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT03121352

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer

Not Applicable

Withdrawn

Conditions: Prostate Cancer

Interventions: Device: MRI guided biopsy
Procedure: TRUS biopsy

First Posted Date: 2017-04-20

Last Posted Date: 2023-03-16

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT03122470

Single Agent Obinutuzumab in Relapsed/Refractory Post-Transplant Lymphoproliferative Disorder (PTLD)

Phase 2

Withdrawn

Conditions: Post-transplant Lymphoproliferative Disorder
PTLD

Interventions: Drug: Obinutuzumab

First Posted Date: 2017-03-22

Last Posted Date: 2017-03-22

Lead Sponsor: Case Comprehensive Cancer Center

Registration Number: NCT03086395

Enhancing Quitline Services for African American Smokers

Not Applicable

Completed

Conditions: Tobacco Use Cessation

Interventions: Behavioral: Standard Care
Behavioral: PTF DVD
Behavioral: smoking cessation DVD

First Posted Date: 2017-02-27

Last Posted Date: 2020-08-19

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 1050

Registration Number: NCT03064971

Locations: 🇺🇸
Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy